This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Steele, V. E. Articles by Kelloff, G. J. Search for Related Content PubMed PubMed Citation Articles by Steele, V. E. Articles by Kelloff, G. J.

Lipoxygenase Inhibitors as Potential Cancer Chemopreventives

Chemoprevention Branch, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892 [V. E. S., E. T. H., L. K., R. A. L., J. A. C., G. J. K.], and CCS Associates, Mountain View, California 94043 [C. A. H., C. C. S.]

Abstract

Mounting evidence suggests that lipoxygenase (LO)-catalyzed products have a profound influence on the development and progression of human cancers. Compared with normal tissues, significantly elevated levels of LO metabolites have been found in lung, prostate, breast, colon, and skin cancer cells, as well as in cells from patients with both acute and chronic leukemias. LO-mediated products elicit diverse biological activities needed for neoplastic cell growth, influencing growth factor and transcription factor activation, oncogene induction, stimulation of tumor cell adhesion, and regulation of apoptotic cell death. Agents that block LO-catalyzed activity may be effective in preventing cancer by interfering with signaling events needed for tumor growth. In fact, in a few studies, LO inhibitors have prevented carcinogen-induced lung adenomas and rat mammary gland cancers.

During the past 10 years, pharmacological agents that specifically inhibit the LO-mediated signaling pathways are now commercially available to treat inflammatory diseases such as asthma, arthritis, and psoriasis. These well-characterized agents, representing two general drug effect mechanisms, are considered good candidates for clinical chemoprevention studies. One mechanism is inhibition of LO activity (5-LO and associated enzymes, or 12-LO); the second is leukotriene receptor antagonism. Although the receptor antagonists have high potential in treating asthma and other diseases where drug effects are clearly mediated by the leukotriene receptors, enzyme activity inhibitors may be better candidates for chemopreventive intervention, because inhibition of these enzymes directly reduces fatty acid metabolite production, with concomitant damping of the associated inflammatory, proliferative, and metastatic activities that contribute to carcinogenesis. However, because receptor antagonists have aerosol formulations and possible antiproliferative activity, they may also have potential, particularly in the lung, where topical application of such formulations is feasible.

This article has been cited by other articles:

				M. J. Edelman, D. Watson, X. Wang, C. Morrison, R. A. Kratzke, S. Jewell, L. Hodgson, A. M. Mauer, A. Gajra, G. A. Masters, et al. Eicosanoid Modulation in Advanced Lung Cancer: Cyclooxygenase-2 Expression Is a Positive Predictive Factor for Celecoxib + Chemotherapy--Cancer and Leukemia Group B Trial 30203 J. Clin. Oncol., February 20, 2008; 26(6): 848 - 855. [Abstract] [Full Text] [PDF]

				P.B. Myrdal, K. Karlage, P.J. Kuehl, B.S. Angersbach, B.A. Merrill, and P.D. Wightman Effects of novel 5-lipoxygenase inhibitors on the incidence of pulmonary adenomas in the A/J murine model when administered via nose-only inhalation Carcinogenesis, May 1, 2007; 28(5): 957 - 961. [Abstract] [Full Text] [PDF]

				L. Du, Z. Zhang, X. Luo, K. Chen, X. Shen, and H. Jiang Binding Investigation of Human 5-Lipoxygenase with Its Inhibitors by SPR Technology Correlating with Molecular Docking Simulation. J. Biochem., April 1, 2006; 139(4): 715 - 723. [Abstract] [Full Text] [PDF]

				J. Hong, S. Sang, H.-J. Park, S. J. Kwon, N. Suh, M.-T. Huang, C.-T. Ho, and C. S. Yang Modulation of arachidonic acid metabolism and nitric oxide synthesis by garcinol and its derivatives Carcinogenesis, February 1, 2006; 27(2): 278 - 286. [Abstract] [Full Text] [PDF]

				M. Edderkaoui, P. Hong, E. C. Vaquero, J. K. Lee, L. Fischer, H. Friess, M. W. Buchler, M. M. Lerch, S. J. Pandol, and A. S. Gukovskaya Extracellular matrix stimulates reactive oxygen species production and increases pancreatic cancer cell survival through 5-lipoxygenase and NADPH oxidase Am J Physiol Gastrointest Liver Physiol, December 1, 2005; 289(6): G1137 - G1147. [Abstract] [Full Text] [PDF]

				R. Hennig, P. Grippo, X.-Z. Ding, S. M. Rao, M. W. Buchler, H. Friess, M. S. Talamonti, R. H. Bell, and T. E. Adrian 5-Lipoxygenase, a Marker for Early Pancreatic Intraepithelial Neoplastic Lesions Cancer Res., July 15, 2005; 65(14): 6011 - 6016. [Abstract] [Full Text] [PDF]

				I. Avis, A. Martinez, J. Tauler, E. Zudaire, A. Mayburd, R. Abu-Ghazaleh, F. Ondrey, and J. L. Mulshine Inhibitors of the Arachidonic Acid Pathway and Peroxisome Proliferator-Activated Receptor Ligands Have Superadditive Effects on Lung Cancer Growth Inhibition Cancer Res., May 15, 2005; 65(10): 4181 - 4190. [Abstract] [Full Text] [PDF]

				N. Li, S. Sood, S. Wang, M. Fang, P. Wang, Z. Sun, C. S. Yang, and X. Chen Overexpression of 5-Lipoxygenase and Cyclooxygenase 2 in Hamster and Human Oral Cancer and Chemopreventive Effects of Zileuton and Celecoxib Clin. Cancer Res., March 1, 2005; 11(5): 2089 - 2096. [Abstract] [Full Text] [PDF]

				X. Chen, S. Wang, N. Wu, S. Sood, P. Wang, Z. Jin, D. G. Beer, T. J. Giordano, Y. Lin, W.-c. J. Shih, et al. Overexpression of 5-Lipoxygenase in Rat and Human Esophageal Adenocarcinoma and Inhibitory Effects of Zileuton and Celecoxib on Carcinogenesis Clin. Cancer Res., October 1, 2004; 10(19): 6703 - 6709. [Abstract] [Full Text] [PDF]

				J. Hong, M. Bose, J. Ju, J.-H. Ryu, X. Chen, S. Sang, M.-J. Lee, and C. S. Yang Modulation of arachidonic acid metabolism by curcumin and related {beta}-diketone derivatives: effects on cytosolic phospholipase A2, cyclooxygenases and 5-lipoxygenase Carcinogenesis, September 1, 2004; 25(9): 1671 - 1679. [Abstract] [Full Text] [PDF]

				J. J. Ochoa, A. J. Farquharson, I. Grant, L. E. Moffat, S. D. Heys, and K. W. J. Wahle Conjugated linoleic acids (CLAs) decrease prostate cancer cell proliferation: different molecular mechanisms for cis-9, trans-11 and trans-10, cis-12 isomers Carcinogenesis, July 1, 2004; 25(7): 1185 - 1191. [Abstract] [Full Text] [PDF]

				N. Osakabe, A. Yasuda, M. Natsume, and T. Yoshikawa Rosmarinic acid inhibits epidermal inflammatory responses: anticarcinogenic effect of Perilla frutescens extract in the murine two-stage skin model Carcinogenesis, April 1, 2004; 25(4): 549 - 557. [Abstract] [Full Text] [PDF]

				E. Kim, S. J. Muga, and S. M. Fischer Identification and Characterization of a Phorbol Ester-responsive Element in the Murine 8S-Lipoxygenase Gene J. Biol. Chem., March 19, 2004; 279(12): 11188 - 11197. [Abstract] [Full Text] [PDF]

				N Nathoo, G H Barnett, and M Golubic The eicosanoid cascade: possible role in gliomas and meningiomas J. Clin. Pathol., January 1, 2004; 57(1): 6 - 13. [Abstract] [Full Text] [PDF]

				J. T. O'Flaherty, L. C. Rogers, B. A. Chadwell, J. S. Owen, A. Rao, S. D. Cramer, and L. W. Daniel 5(S)-Hydroxy-6,8,11,14-E,Z,Z,Z-eicosatetraenoate Stimulates PC3 Cell Signaling and Growth by a Receptor-dependent Mechanism Cancer Res., December 1, 2002; 62(23): 6817 - 6819. [Abstract] [Full Text] [PDF]

				X. Chen, N. Li, S. Wang, J. Hong, M. Fang, J. Yousselfson, P. Yang, R. A. Newman, R. A. Lubet, and C. S. Yang Aberrant arachidonic acid metabolism in esophageal adenocarcinogenesis, and the effects of sulindac, nordihydroguaiaretic acid, and {alpha}-difluoromethylornithine on tumorigenesis in a rat surgical model Carcinogenesis, December 1, 2002; 23(12): 2095 - 2102. [Abstract] [Full Text] [PDF]

				L. R. Kisley, B. S. Barrett, L. D. Dwyer-Nield, A. K. Bauer, D. C. Thompson, and A. M. Malkinson Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice Carcinogenesis, October 1, 2002; 23(10): 1653 - 1660. [Abstract] [Full Text] [PDF]

				W. T. Gunning, P. M. Kramer, V. E. Steele, and M. A. Pereira Chemoprevention by Lipoxygenase and Leukotriene Pathway Inhibitors of Vinyl Carbamate-induced Lung Tumors in Mice Cancer Res., August 1, 2002; 62(15): 4199 - 4201. [Abstract] [Full Text] [PDF]

				J. M. Wallace Nutritional and Botanical Modulation of the Inflammatory Cascade--Eicosanoids, Cyclooxygenases, and Lipoxygenases-- As an Adjunct in Cancer Therapy Integr Cancer Ther, March 1, 2002; 1(1): 7 - 37. [Abstract] [PDF]

				I. Shureiqi and S. M. Lippman Lipoxygenase Modulation to Reverse Carcinogenesis Cancer Res., September 1, 2001; 61(17): 6307 - 6312. [Abstract] [Full Text] [PDF]

				X. Chen and C. S. Yang Esophageal adenocarcinoma: a review and perspectives on the mechanism of carcinogenesis and chemoprevention Carcinogenesis, August 1, 2001; 22(8): 1119 - 1129. [Abstract] [Full Text] [PDF]

				K. Krishnan, M. T. Ruffin, D. Normolle, I. Shureiqi, K. Burney, J. Bailey, M. Peters-Golden, C. L. Rock, C. R. Boland, and D. E. Brenner Colonic Mucosal Prostaglandin E2 and Cyclooxygenase Expression before and after Low Aspirin Doses in Subjects at High Risk or at Normal Risk for Colorectal Cancer Cancer Epidemiol. Biomarkers Prev., May 1, 2001; 10(5): 447 - 453. [Abstract] [Full Text]

				J. A. Williams and D. H. Phillips Mammary Expression of Xenobiotic Metabolizing Enzymes and Their Potential Role in Breast Cancer Cancer Res., September 1, 2000; 60(17): 4667 - 4677. [Abstract] [Full Text]

				I. Shureiqi, D. Chen, J. J. Lee, P. Yang, R. A. Newman, D. E. Brenner, R. Lotan, S. M. Fischer, and S. M. Lippman 15-LOX-1: a Novel Molecular Target of Nonsteroidal Anti-inflammatory Drug-Induced Apoptosis in Colorectal Cancer Cells J Natl Cancer Inst, July 19, 2000; 92(14): 1136 - 1142. [Abstract] [Full Text] [PDF]